These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
132 related items for PubMed ID: 2877855
1. Sulphasalazine for rheumatoid arthritis. Studies on dose, acetylator phenotype and efficacy. Amos RS, Bax DE, Greaves MS. Drugs; 1986; 32 Suppl 1():58. PubMed ID: 2877855 [No Abstract] [Full Text] [Related]
2. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review. Pullar T, Capell HA. Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854 [Abstract] [Full Text] [Related]
3. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Bax DE, Greaves MS, Amos RS. Br J Rheumatol; 1986 Aug; 25(3):282-4. PubMed ID: 2873862 [Abstract] [Full Text] [Related]
7. Symposium on enteric-coated sulphasalazine in rheumatoid arthritis. Proceedings of a symposium. London, December 6, 1985. Drugs; 1986 Aug; 32 Suppl 1():1-80. PubMed ID: 2877848 [No Abstract] [Full Text] [Related]
8. History of the development of sulphasalazine in rheumatology. McConkey B. Drugs; 1986 Aug; 32 Suppl 1():12-7. PubMed ID: 2877849 [No Abstract] [Full Text] [Related]
9. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? Taggart AJ, Neumann VC, Hill J, Astbury C, Le Gallez P, Dixon JS. Drugs; 1986 Aug; 32 Suppl 1():27-34. PubMed ID: 2877851 [Abstract] [Full Text] [Related]
10. Sulfasalazine-induced aseptic meningitis with positive rechallenge: a case report and review of the literature. Salouage I, El Aïdli S, Cherif F, Kastalli S, Zaiem A, Daghfous R. Therapie; 2013 Aug; 68(6):423-6. PubMed ID: 24356191 [No Abstract] [Full Text] [Related]
11. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results. Georgescu C. Rom J Intern Med; 1992 Aug; 30(2):127-32. PubMed ID: 1353901 [Abstract] [Full Text] [Related]
13. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Kitas GD, Farr M, Waterhouse L, Bacon PA. Scand J Rheumatol; 1992 Sep; 21(5):220-5. PubMed ID: 1359635 [Abstract] [Full Text] [Related]
14. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Taggart AJ, McDermott B, Delargy M, Elborn S, Forbes J, Roberts SD, Ahnfelt NO. Scand J Rheumatol Suppl; 1987 Sep; 64():29-36. PubMed ID: 2893450 [Abstract] [Full Text] [Related]
15. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Pullar T, Hunter JA, Capell HA. Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876 [Abstract] [Full Text] [Related]
16. Pharmacological and biochemical actions of sulphasalazine. Hoult JR. Drugs; 1986 Aug; 32 Suppl 1():18-26. PubMed ID: 2877850 [Abstract] [Full Text] [Related]
17. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. Chalmers IM, Sitar DS, Hunter T. J Rheumatol; 1990 Jun; 17(6):764-70. PubMed ID: 1974926 [Abstract] [Full Text] [Related]
18. [Treatment with leflunomide in rheumatoid arthritis]. Krüger K, Bolten W. Z Rheumatol; 2005 Mar; 64(2):96-101. PubMed ID: 15793675 [No Abstract] [Full Text] [Related]